NVS » Topics » Voltaren

This excerpt taken from the NVS 6-K filed Feb 9, 2010.
Voltaren (USD 797 million, +1% lc, excluding OTC sales), a treatment for various inflammation and pain conditions, no longer has patent protection in key markets around the world, but has continued to generate growth in regions such as Latin America, the Middle East, Africa and Asia based on long-term trust in the brand.

 

This excerpt taken from the NVS 6-K filed Feb 9, 2009.
Voltaren (USD 814 million, +3% lc, excluding OTC sales), a treatment for inflammation and pain, no longer has patent protection in key markets around the world, but has continued to generate consistent growth in regions such as Latin America, the Middle East, Africa and Asia based on long-term trust in the brand.

 

This excerpt taken from the NVS 6-K filed Feb 8, 2008.
Voltaren (USD 747 million, +3% lc), a therapy for inflammation and pain, showed steady growth, primarily in Latin America and Asia, based on long-term trust in the brand. Patent protection for
This excerpt taken from the NVS 6-K filed Jan 23, 2008.
Voltaren (USD 747 million, +3% lc), a therapy for inflammation and pain, showed steady growth, primarily in Latin America and Asia, based on long-term trust in the brand. Patent

 

14



 

protection for Voltaren in many key markets around the world has expired.

 

This excerpt taken from the NVS 6-K filed Feb 14, 2007.
Voltaren is a branded pain relief drug sold primarily in Europe where it is off patent in most countries. Novartis applies a straight-line amortization period and the useful life is considered to end in 2011.

This excerpt taken from the NVS 20-F filed Jan 31, 2007.

Voltaren

        Voltaren is a branded pain relief drug sold primarily in Europe where it is off patent in most countries. Novartis applies a straight-line amortization period and the useful life is considered to end in 2011.

This excerpt taken from the NVS 6-K filed Apr 27, 2006.
Voltaren in Europe supported OTC. Animal Health delivered double-digit growth, with sales spread more evenly over the year compared to prior years. Gerber delivered mid-single-digit growth, while Medical Nutrition sales remained flat. CIBA Vision sales were lower, impacted by ongoing remediation of a lens-care product supply issue.

 

3



 

This excerpt taken from the NVS 6-K filed Feb 8, 2006.

VOLTAREN

Voltaren is a branded pain relief drug sold primarily in Europe where it is off patent in most countries. Novartis applies a straight-line amortization period and the useful life is considered to end in 2011.

This excerpt taken from the NVS 20-F filed Jan 30, 2006.

Voltaren

        Voltaren is a branded pain relief drug sold primarily in Europe where it is off patent in most countries. Novartis applies a straight-line amortization period and the useful life is considered to end in 2011.

This excerpt taken from the NVS 6-K filed Feb 4, 2005.

Voltaren

Voltaren is off-patent in the US and many other countries. Novartis applies a straight-line amortization period and the useful life ends in 2011.

This excerpt taken from the NVS 20-F filed Jan 28, 2005.

Voltaren

        Voltaren is off-patent in the US and many other countries. Voltaren as a branded product has had approximately $600 million of sales outside of the US in each of the past three years. Novartis applies a straight-line amortization period and the useful life ends in 2011.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki